These therapeutics are based on the human genome, according to Epizyme CEO Robert Gould.
“Understanding the DNA composition of cancer cells would enable one to target very particular cancer cells, so that a particular genetic alteration that was causing those cells to grow abnormally,” Gould says "
Click here to read the whole article
Shares of the developmental stage cancer company Epizyme went ballistic in afterhours trading yesterday, rising over 34% on heavy volume,Read more
Epizyme will book a $25 million payment after a potential leukemia treatment reached an early milestone, sending company shares rocketingRead more
Epizyme logo Epizyme (NASDAQ:EPZM) CFO Jason Rhodes unloaded 10,000 shares of the company's stock in a transaction dated Monday,Read more